Ones To Watch News
Refine Search
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Biotechnology
In a transaction aimed at creating a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, Boston, USA-based biotech Solid Biosciences on Friday announced that it has entered into a definitive merger agreement to acquire fellow gene therapy biotech AavantiBio. 3 October 2022
Pharmaceutical
The US Food and Drug Administration yesterday approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease. 30 September 2022
Pharmaceutical
Massachusetts-based biotech Ventus Therapeutics has entered into an exclusive global licensing deal with Danish diabetes giant Novo Nordisk. 30 September 2022
Biotechnology
Shares of Axcella Therapeutics were up almost 20% at $2.07 pre-market, after the US biotech said its experimental treatment for the challenging disease area of non-alcoholic steatohepatitis (NASH) showed statistically-significant improvement in liver stiffness. 29 September 2022
Biotechnology
A new UK-based antibody-drug conjugate (ADC) company, Pheon Therapeutics, has launched with $68 million in series A backing. 28 September 2022
Biotechnology
Californian genetic medicine company Scribe Therapeutics has scored a major strategic collaboration with French giant Sanofi. 27 September 2022
Biotechnology
KiOmed Pharma, a Belgian biotech developing medical devices based on a highly pure natural chitosan-derivative, has announced a deal with China’s Hansoh Pharmaceutical Group. 27 September 2022
Biotechnology
Ionis Pharmaceuticals’ shares were down 6.6% pre-market today, after the company released new data on its hypercholesterolemia candidate ION499 that failed to impress its development partner. 23 September 2022
Biotechnology
Inventiva, which is making solid progress with its candidate for the highly challenging non-alcoholic steatohepatitis (NASH) indication, saw its shares shoot up more than 25% to 5.06 euros yesterday, after the French biotech announced a lucrative licensing deal for its drug lanifibranor in China. 23 September 2022
Pharmaceutical
UK-based GSK’s latest deal has defied the long-term trend among big pharma companies to move investment away from the high-risk, low returns antibiotic space. 22 September 2022
Biotechnology
Shares of US biotech Sesen Bio (Nasdaq: SESN) tumbled nearly 33% to $0.45 by close of trading yesterday, after it revealed a plan to merge with privately-held Carisma Therapeutics. 22 September 2022
Biotechnology
Coeptis Therapeutics has raided the nearby University of Pittsburgh in the latest step towards realizing the company’s aim of disrupting conventional treatment paradigms. 21 September 2022
Biotechnology
A drug candidate that Japan’s largest drugmaker Takeda Pharmaceutical pretty much decided to discontinue back in 2015, has now been out-licensed in a deal that could earn the firm nearly $300 million should it prove successful, albeit with a modest upfront payment. 21 September 2022
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued a final appraisal document (FAD) recommending Brukinsa (zanubrutinib). 21 September 2022
Biotechnology
In an all-stock deal valued at around $53 million, Rocket Pharmaceuticals is to acquire fellow US biotech firm Renovacor. 20 September 2022
Biotechnology
Belgium’s NeuVasQ Biotechnologies, a Université Libre de Bruxelles (ULB) spin-off developing pharmaceuticals to restore blood-brain barrier function, has named Emmanuel Lacroix chief executive and company director. 20 September 2022
Pharmaceutical
The European Commission (EC) has granted marketing authorization for Nulibry (fosdenopterin) for Injection as the first therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. 20 September 2022
Pharmaceutical
Sage Therapeutics closed up 3.8% at $42.14 on Tuesday after, along with partner Biogen, it announced new analyses from across the development program for zuranolone. 20 September 2022
Biotechnology
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announced the appointment of Susan Nichols to its senior management team as chief business officer (CBO). 20 September 2022
Pharmaceutical
The European Commission (EC) has granted marketing authorization of Lupkynis (voclosporin) to treat adults with active lupus nephritis (LN). This follows the positive European Medicines Agency’s CHMP opinion announced in late July. 20 September 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze